Macular Degeneration Treatment MarketSize and Trends
Market Statistics:
The global macular degeneration treatment market was valued at US$ 8,208.7 Mn in 2021 and is forecast to reach a value of US$ 13,195.7 Mn by 2028 at a CAGR of 7.0% between 2022 and 2028.
North America held dominant position in the global macular degeneration treatment market in 2020, accounting for 38.5% share in terms of volume, followed by Europe and Asia Pacific, respectively.
Figure 1. Global Macular Degeneration Treatment Market Share (%), by Region, 2021
![](/images/research-%20methodology/724388global-macular-degeneration-treatment-market-fig-1.png)
Market Trends/Key Takeaways:
- Frequent approvals and launches of novel products is expected to drive growth of the global macular degeneration treatment market. For instance, in October 2021, Roche announced that the Food and Drug Administration (FDA) has approved Susvimo (100 mg/mL ranibizumab injection) for the treatment of wet, or neovascular, age-related macular degeneration (AMD), a condition that can lead to rapid and severe loss of vision.
- Introduction of novel products by market players is expected to augment the growth of the global macular degeneration treatment market. For instance, in September 2019, Boehringer Ingelheim and Inflammasome Therapeutics Inc. signed an agreement to develop three therapies for patients suffering with retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).